JP2024533264A - 神経原性疾患を処置するための方法 - Google Patents

神経原性疾患を処置するための方法 Download PDF

Info

Publication number
JP2024533264A
JP2024533264A JP2024514643A JP2024514643A JP2024533264A JP 2024533264 A JP2024533264 A JP 2024533264A JP 2024514643 A JP2024514643 A JP 2024514643A JP 2024514643 A JP2024514643 A JP 2024514643A JP 2024533264 A JP2024533264 A JP 2024533264A
Authority
JP
Japan
Prior art keywords
methyl
pyrimidin
chloro
amine
aminopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533264A5 (https=
Inventor
スコット ジェイ バラザ
ジェフリー ケイ トリマー
ヨン ユ
シャオヤン チャン
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2024533264A publication Critical patent/JP2024533264A/ja
Publication of JP2024533264A5 publication Critical patent/JP2024533264A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024514643A 2021-09-07 2022-09-06 神経原性疾患を処置するための方法 Pending JP2024533264A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163260944P 2021-09-07 2021-09-07
US63/260,944 2021-09-07
PCT/US2022/075969 WO2023039370A1 (en) 2021-09-07 2022-09-06 Methods for treating neurogenerative diseases

Publications (2)

Publication Number Publication Date
JP2024533264A true JP2024533264A (ja) 2024-09-12
JP2024533264A5 JP2024533264A5 (https=) 2025-09-17

Family

ID=85506888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514643A Pending JP2024533264A (ja) 2021-09-07 2022-09-06 神経原性疾患を処置するための方法

Country Status (7)

Country Link
US (1) US20240374602A1 (https=)
EP (1) EP4398988A4 (https=)
JP (1) JP2024533264A (https=)
CN (1) CN118401243A (https=)
CA (1) CA3231001A1 (https=)
MX (1) MX2024002887A (https=)
WO (1) WO2023039370A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2012012656A2 (en) * 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
CN115209955A (zh) * 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物

Also Published As

Publication number Publication date
EP4398988A4 (en) 2025-07-09
EP4398988A1 (en) 2024-07-17
CN118401243A (zh) 2024-07-26
CA3231001A1 (en) 2023-03-16
WO2023039370A1 (en) 2023-03-16
US20240374602A1 (en) 2024-11-14
MX2024002887A (es) 2024-05-28

Similar Documents

Publication Publication Date Title
EP4288441A1 (en) Methods for treating spinocerebellar ataxia type 3
US12398140B2 (en) Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
US10787433B2 (en) Pyridazine derivatives as EAAT2 activators
WO2023250316A1 (en) Compounds for treating spinocerebellar ataxia type 3
EP4288059A1 (en) Compounds for treating spinocerebellar ataxia type 3
US11377436B2 (en) EAAT2 enhancing molecules
US20150274716A1 (en) Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions and their use
JP2025133750A (ja) 家族性自律神経失調症を処置するための化合物
JP2024533264A (ja) 神経原性疾患を処置するための方法
JP2024533263A (ja) 神経原性疾患を処置するための方法
JP2024533323A (ja) 神経変性疾患を処置するための方法
US20240051968A1 (en) Methods for treating spinocerebellar ataxia type 3
US20240041886A1 (en) Methods for treating spinocerebellar ataxia type 3
US9489013B2 (en) C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
US20240376111A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
US20250066356A1 (en) Lrrk2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250905